Selurampanel

Drug Profile

Selurampanel

Alternative Names: BGG-492; BGG-492A

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Antiepileptic drugs; Pyrazoles; Sulfonamides
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Partial epilepsies
  • No development reported Epilepsy; Migraine; Tinnitus

Most Recent Events

  • 01 Sep 2015 Novartis completes a phase II safety follow-up trial in patients with Partial epilepsies in USA, Germany, Hungary, Italy, Slovakia and South Korea (NCT02150213)
  • 23 Jun 2015 Selurampanel is still in phase II trials for Partial epilepsies (Adjunctive treatment)
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Migraine in USA, Germany and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top